Jectatest/Depo/Malogen CYP/Testosterone cyclopentylpropionate/Durandro/Testodrin prolongatum/Andro-Cyp/(8R,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl-3-cyclopentylpropanoat/Pertestis/VIRILON/Testosterone 17b-Cypionate/Testosterone 17β-cyclopentanepropionate/4-09-00-00048/depAndro 200/depAndro 100/Testosterone cypionate/DEPOVIRIN/Testosterone, cyclopentanepropionate/Testosterone 17b-Cyclopentanepropionate/depo-testosterone/3-cyclopentylpropanoate de (8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yle/Testosterone 17β-cypionate/(17β)-3-Oxoandrost-4-en-17-yl 3-cyclopentylpropanoate/Cyclopentanepropanoic acid, (17β)-3-oxoandrost-4-en-17-yl ester/Depotest/17b-(3-Cyclopentyl-1-oxopropoxy)androst-4-en-3-one/Testergon/Testex Leo/Depo-testosterone cyclopentylpropionate/Dep-Test/T-Ionate-P.A/Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17β)-/(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl 3-cyclopentylpropanoate/Androst-4-en-3-one, 17- (3-cyclopentyl-1-oxopropoxy)-, (17β)-/Testosteronecypionate
525.9±50.0 °C at 760 mmHg
98 - 104ºC
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:58-20-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Testosterone cypionate and Stanozolol are Anabolic-Androgenic Steroids (AAS) which are synthetic substances that possess functions similar to testosterone. The use of these substances has increased considerably among youngsters and sports practitioners aiming better performance of with aesthetic purposes. The major concern is the effects caused by the inappropriate use of the substances, such as hypertension, myocardial ischemia, and left ventricle hypertrophy. The objective of the present research was to measure the diameter of the left ventricle lumen and the thickness of the left ventricle myocardium in mice submitted to supraphysiological doses of AAS. A total of 30 female Swiss mice were used in the experiments. The animals received supraphysiological doses of the AAS for 30 days, and during the treatment period, they were put to swim in intercalated days. After treatment animals were euthanized and slides were made from the hearts for measurements. Results demonstrated that both AAS changed significantly the heart morphology: Testosterone cypionate led to an increase in the ventricular lumen and stanozolol increased left ventricle myocardium thickness. In conclusion, the use of AAS in supraphysiological doses can change the heart morphology and can lead to serious health consequences.
Copyright © 2019 Elsevier Inc. All rights reserved.
Heart; Stanozolol; Testosterone cypionate; Ventricle myocardium
Effect of testosterone cypionate and stanozolol on the heart of young trained mice: A morphometric study.
Vieira TM1, Rossi Junior WC1, Da Re Guerra F1, Damião B2, Marques PP3, Esteves A4.
A randomized, double-blind clinical trial was conducted to investigate long-term abuse effects of testosterone cypionate (TC). Thirty-one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link exposure to change in luteinizing hormone and spermatogenesis following long-term TC administration. A linear one-compartment model best described the concentration-time profile of total testosterone. The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe and of greater duration in the 250 mg and the 500 mg dose groups.
© 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.
Bi Y1, Perry PJ1,2, Ellerby M2, Murry DJ3.
Urethral sphincter mechanism incompetence (USMI) is reported much more seldom in male dogs than in female dogs. The few existing reports evaluating the efficacy of medical therapy in controlling USMI in males have demonstrated limited success. In this case series, we report the effect of testosterone cypionate, given at a median dose of 1.5 mg/kg intramuscularly every 4 wk, in eight male dogs with USMI. Response was evaluated through the review of medical records and telephone interviews with the clients. Based on owners’ assessments, a good to excellent response was reported in three of eight dogs (38%), a slight response was reported in one of eight dogs (12%), and a poor response was reported in four of eight dogs (50%). Adverse effects were not reported, and benefit was judged sufficient to continue therapy in two cases. The results reported in this case series suggest that testosterone cypionate might be an effective and safe treatment option for male dogs with USMI.
Clinical Response and Side Effects Associated with Testosterone Cypionate for Urinary Incontinence in Male Dogs.
Palerme JS1, Mazepa A1, Hutchins RG1, Ziglioli V1, Vaden SL1.